Researchers with Indiana University School of Medicine Department of Obstetrics and Gynecology, Department of Pediatrics and Division of Clinical Pharmacology in the Department of Medicine are studying how certain drugs and medications affect pregnant and lactating women and their children thanks to a new, five-year, $17.1 million grant from the National Institutes of Health.
Indiana University School of Medicine researchers worked in collaboration with an international team of scientists to uncover why certain children get recurring urinary tract infections (UTIs) and others do not.
Indiana University School of Medicine has named Reuben Kapur, PhD, as the director of the Herman B Wells Center for Pediatric Research and the Department of Pediatrics vice chair for basic science research. Kapur has held the roles in an interim capacity since November 2019.
A group of researchers based at Indiana University School of Medicine and Riley Hospital for Children at IU Health has discovered that people who are clinically lacking androgen effects are three to four times more likely to have asthma than people in the general population.
INDIANAPOLIS—For the fifth-straight year, Indiana University School of Medicine set a school record for research funding received from the National Institutes of Health, showcasing its continued leadership in the field of medical research.
Researchers are learning more about ways to predict the likelihood of newborn complications from early in pregnancy using samples provided by the Indiana University School of Medicine Building Blocks of Pregnancy Biobank.
A group of researchers including Chandy John, MD, from Indiana University School of Medicine, published a study in the New England Journal of Medicine showing malaria chemoprevention reduces morbidity and mortality in children with severe anemia.
Researchers at Indiana University School of Medicine have published their work about a specific type of childhood cancer in the peer-reviewed, international oncology journal, Cancers. This research involves a combination therapy that significantly slows tumor growth in models, which includes a model established from cells taken from tumors donated by Tyler Trent.